Remedy Plan Therapeutics

We were proud to attend The Leukemia & Lymphoma Society's ✨Light The Night ✨ event in Washington, DC this past weekend. This inspiring evening brought together survivors, caregivers, supporters, and advocates, united by a shared mission: to raise awareness and funds to fight blood cancers like leukemia, lymphoma, and myeloma. At the heart of LLS's mission is a commitment to advancing research, supporting patients, and providing hope to families facing these diseases. Events like Light The Night are a powerful reminder of the strength within this community and the impact we can make together.  We are honored to stand with LLS in their efforts and remain committed to supporting their vision of a world without blood cancer.🌎 #BloodCancer #Leukemia #Lymphoma #LLS #LightTheNight

This October 25th, we recognize MDS Awareness Day, an opportunity to raise awareness about Myelodysplastic Syndromes (MDS) a group of rare blood cancers that arise when blood-forming cells in the bone marrow become abnormal, leading to ineffective blood cell production. MDS can progress to acute myeloid leukemia (AML), a more aggressive form of blood cancer. With thousands of new MDS cases diagnosed annually, particularly in older adults, the need for innovative treatments remains critical. At Remedy Plan, we are committed to transforming care for these patients. Our unique NAMPT inhibitor, RPT1G, is showing encouraging potential in preclinical studies for AML, and may have potential for MDS. On MDS Awareness Day, we encourage everyone to learn more, spread the word, and support the fight against MDS. Together, we can make a difference for patients and their families. #MDSAwarenessDay #BloodCancerAwareness #MDSResearch #HealthcareInnovation

NAMPT is widely considered a high value drug target across oncology, autoimmune disease, and metabolic disease. Currently, there are no FDA approved NAMPT drugs; however, it has been a focus for pharma companies in the last 10 years including AbbVie, Eli Lilly, Genentech, Astellas, Novartis, Karyopharm, OncoTartis, and LEO Pharma. A safe and efficacious NAMPT drug could address multiple markets with significant unmet needs, comprising a global market value of >$142 billion in oncology and >$284 billion in autoimmune and metabolic disease. Our clinical candidate, RPT1G, is a first-in-class NAMPT inhibitor that has the potential to address these multiple markets - its safety and efficacy have been demonstrated in preclinical cancer models. We will be taking RPT1G to the clinic later this year. #NAMPT #NAMPTinhibition #innovation

Earlier this week we shared a poll 📊 asking in what ways NAMPT expression and activity vary – the answer was D) All of the above. NAMPT expression and activity vary across different organelles, tissues, and even depending on the time of day! 🕑 NAMPT expression and its impact on circadian rhythm varies significantly across different tissues and cell types, with the most prominent effect observed in adipose tissue, where it plays a crucial role in regulating fat metabolism by influencing the circadian clock within fat cells. The level of NAMPT dependence on the circadian clock differs depending on the tissue type involved. This variance is important to understand when exploring new treatments for metabolic diseases, including obesity. A 2023 study by Novo Nordisk discusses NAMPT’s link to circadian rhythm (Basse, et al.). The study reveals that NAMPT has rhythmic activity that varies across adipose tissue and skeletal muscle. Disrupting NAMPT expression in fat cells specifically dampens several core circadian clock genes and the circadian rhythmicity of several lipid metabolism genes, which influences how the body stores and uses fats. The same effect was not seen in skeletal muscle. Another study by Novo Nordisk shows that NAMPT contributes significantly to obesity and is in fact, necessary for increasing fat mass and dispensable for maintaining lean mass.  (Nielsen, et al.). Results showed that NAMPT found in adipose tissue substantially affects dietary lipids and their role in vital processes such as food intake. Here at Remedy Plan, we are exploring the application of our 1st-in-class NAMPT inhibitors in metabolic disease. ---------------------------------------------------------------------------  Basse AL, et al. NAMPT-dependent NAD+ biosynthesis controls circadian metabolism in a tissue-specific manner. Proc Natl Acad Sci U S A. 2023 Apr 4;120(14):e2220102120. doi: 10.1073/pnas.2220102120. Nielsen KN, et al. NAMPT-mediated NAD+ biosynthesis is indispensable for adipose tissue plasticity and development of obesity. Mol Metab. 2018 May;11:178-188. doi: 10.1016/j.molmet.2018.02.014.  

As this #BloodCancerAwarenessMonth comes to an end, we reflect on the critical need for continued innovation in the treatment of blood cancers like ALL, AML, lymphoma, and more. While we have made progress, there remains a significant unmet need for new treatment options to improve the lives of patients battling these devastating diseases. At the heart of our efforts, we are always reminded of the patients and their families. Their strength and resilience drive us to push the boundaries of what’s possible in research and drug development. We are committed to keeping them at the forefront of everything we do, ensuring that our work is not just about science, but about making a meaningful difference. We also want to take a moment to acknowledge the incredible work of organizations like The Leukemia & Lymphoma Society. Their dedication to supporting patients, funding research, and advancing care through philanthropy is invaluable. Together, we can continue to work toward a future where blood cancers are not only more treatable, but where outcomes are significantly improved for patients. #BCAM #BCAM2024 #LLS

Time for a Remedy Plan poll! 📊 This week we're diving into NAMPT's role and value as a target in metabolic disease. Tune in later this week as we reveal the answer to this poll and explore some recent publications on this topic. 📰

Earlier this week we shared a poll 📊 asking which immune cells are modulated by NAMPT activity – T Cells, B Cells, and macrophages are all impacted! NAMPT has been a point of interest and growing area of research for autoimmune diseases due to its direct impact on immunometabolism and its dysregulation in multiple autoimmune diseases. A 2019 study by our scientific advisory board members Dr. Ed Pearce and Dr. Erika Pearce shows that NAMPT plays a significant role in the inflammatory responses from macrophages (Cameron, et al.) A 2018 study (Gerner, et al.) shows that NAMPT expression is a critical component in human and mouse intestinal inflammatory pathways and highlights that NAMPT blockade could serve as a promising path in intestinal inflammation. In preclinical studies, our hyperbolic NAMPT inhibitors have been shown to modulate immunometabolism and we plan to continue expanding our development of NAMPT inhibitors for autoimmune disease. 👩🔬 ------------------------------------------- Cameron AM, Castoldi A, Sanin DE, Flachsmann LJ, Field CS, Puleston DJ, Kyle RL, Patterson AE, Hässler F, Buescher JM, Kelly B, Pearce EL, Pearce EJ. Inflammatory macrophage dependence on NAD+ salvage is a consequence of reactive oxygen species-mediated DNA damage. Nat Immunol. 2019 Apr;20(4):420-432. doi: 10.1038/s41590-019-0336-y. Gerner RR, Klepsch V, Macheiner S, Arnhard K, Adolph TE, Grander C, Wieser V, Pfister A, Moser P, Hermann-Kleiter N, Baier G, Oberacher H, Tilg H, Moschen AR. NAD metabolism fuels human and mouse intestinal inflammation. Gut. 2018 Oct;67(10):1813-1823. doi: 10.1136/gutjnl-2017-314241.

Our CEO and Founder Gregory Crimmins, PhD shared scientific and company updates in a presentation at the UBS 2024 Biotechnology Private Company Virtual Symposium on Thursday, September 19, 2024. 📺 Watch the archived presentation here: https://lnkd.in/eyRXNNum

During #BloodCancerAwarenessMonth, we are reminded of the profound impact blood cancers have on countless lives. Organizations like The Leukemia & Lymphoma Society play an essential role in providing vital support to patients and their families through these challenging journeys. #BCAM24 #bloodcancer #LLS

Time for another poll! 📊 This week we are exploring NAMPT's role in autoimmune disease.